RCKT Form 144: Insider Sale of 699 Shares Planned on 08/18/2025

Form 144 notice for Rocket Pharmaceuticals, Inc. (RCKT): The filing notifies a proposed sale of 699 common shares through Fidelity Brokerage Services LLC on 08/18/2025, with an aggregate market value of $2,142.57.

Rhea-AI Filing Summary

Form 144 notice for Rocket Pharmaceuticals, Inc. (RCKT): The filing notifies a proposed sale of 699 common shares through Fidelity Brokerage Services LLC on 08/18/2025, with an aggregate market value of $2,142.57. The shares were acquired by the seller via restricted stock vesting on 08/14/2025 and were issued as compensation. The filing also reports sales by the same person earlier this year: 357 shares sold on 05/20/2025 for $2,301.22 and 7,043 shares sold on 08/14/2025 for $21,260.70. The issuers outstanding shares are listed as 107,903,871.

Insights

Securities Analyst

TL;DR: Routine insider sale following restricted stock vesting; amounts disclosed are small in absolute dollar terms.

The Form 144 documents a proposed sale of 699 common shares acquired via restricted stock vesting on 08/14/2025 and intended to be sold on 08/18/2025 through Fidelity. Two prior sales by the same person earlier in 2025 are disclosed, totaling 7,400 shares. The filing meets Rule 144 disclosure requirements by identifying acquisition dates, nature of acquisition (compensation), broker, and proceeds. From a trading-impact perspective, these transactions appear routine and procedural rather than materially transformative for the issuer.

Corporate Governance Expert

TL;DR: Disclosure is complete for the transactions shown; this appears to be standard compliance with insider sale rules.

The filer indicates the securities were issued as compensation and vested on 08/14/2025, with planned sale on 08/18/2025. The notice includes prior sales in the past three months, consistent with aggregation requirements. The signer attests they possess no undisclosed material adverse information. This filing documents compliance with Rule 144 and provides transparent traceability of insider dispositions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 for RCKT disclose about the planned sale?

The notice reports a proposed sale of 699 common shares via Fidelity Brokerage Services on 08/18/2025, with aggregate market value $2,142.57.

How were the 699 shares acquired according to the filing?

The filing states the shares were acquired on 08/14/2025 through restricted stock vesting and issued as compensation.

Who is the seller named in the Form 144 and what prior sales are reported?

The filing lists John Militello and reports prior sales of 357 shares on 05/20/2025 for $2,301.22 and 7,043 shares on 08/14/2025 for $21,260.70.

What outstanding share count does the filing show for the issuer?

The Form 144 lists 107,903,871 shares outstanding for the issuer.

Does the filing state whether the seller knows any undisclosed material information?

Yes. By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2025 - 03:10 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001662170
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROCKET PHARMACEUTICALS, INC.
SEC File Number	001-36829
Address of Issuer	350 FIFTH AVENUE SUITE 7530 NEW YORK NEW YORK 10118
Phone	646-440-9100
Name of Person for Whose Account the Securities are To Be Sold	Militello John
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	699	2142.57	107903871	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/14/2025	Restricted Stock Vesting	Issuer			699	08/14/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John Militello 9 Cedarbrook Drive Cranbury NJ 08512	Common	05/20/2025	357	2301.22
John Militello 9 Cedarbrook Drive Cranbury NJ 08512	Common	08/14/2025	7043	21260.70

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	08/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for John Militello
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)